QuidelOrtho Corp QDEL
The biggest changes in the 10-K filed Feb 19, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Dec 28, 2025 vs Dec 29, 2024
“Research and development expense for fiscal year ended 2025 decreased by $32.5 million, or 14.9%, to $186.2 million from $218.7 million for the prior year, primarily due to lower third-party material and outside service spend, compensation costs and clinical costs related to cost-savings initiatives actioned in 2024.”
Read it in the 10-K
Cash from operations
Big change, FY to Dec 28, 2025 vs Dec 29, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Dec 28, 2025 vs Dec 29, 2024
“Labs revenue increased 6% compared to the prior year, primarily due to growth in reagents, consumables and services, partially offset by a decline in instrument revenue.”
Read it in the 10-K
“Immunohematology revenue increased 4% compared to the prior year, primarily due to reagent growth.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 -1.9%
“Labs revenue increased 6% compared to the prior year, primarily due to growth in reagents, consumables and services, partially offset by a decline in instrument revenue.”
Read it in the FY 2025 10-K“Immunohematology revenue increased 4% compared to the prior year, primarily due to reagent growth.”
Read it in the FY 2025 10-K -
FY 2024 -7.2%
“The increase in Labs revenue was primarily related to growth in reagents, consumables and services, partially offset by decreased COVID-19 and non-core revenue compared to the prior year.”
Read it in the FY 2024 10-K“Immunohematology revenue increased 2% compared to the prior year period, primarily due to reagent growth.”
Read it in the FY 2024 10-K
Operating margin
2 of 2 years explained-
FY 2025 +36.8 pts
“Research and development expense for fiscal year ended 2025 decreased by $32.5 million, or 14.9%, to $186.2 million from $218.7 million for the prior year, primarily due to lower third-party material and outside service spend, compensation costs and clinical costs related to cost-savings initiatives actioned in 2024.”
Read it in the FY 2025 10-K -
FY 2024 -75.1 pts
“Research and development expense for fiscal year ended 2024 decreased by $26.3 million, or 10.7%, to $218.7 million from $245.0 million for the prior year, primarily due to lower employee compensation costs and costs of outside services.”
Read it in the FY 2024 10-K
Cash from operations
0 of 2 years explained-
FY 2025 +26.7%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 -70.4%
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.